FDA.reportPublic FDA data

3 ML insulin glargine-aglr 100 UNT/ML Pen Injector

RxCUI
2589008
RxNorm name
3 ML insulin glargine-aglr 100 UNT/ML Pen Injector
Display name
3 ML insulin glargine-aglr 100 UNT/ML Pen Injector
Full name
3 ML insulin glargine-aglr 100 UNT/ML Pen Injector
Term type
SCD
Status
DailyMed mapping
Updated
2026-06-04 23:39:28

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761215Rezvoglarinsulin glargine-aglr351(k) InterchangeableRx2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Rezvoglar KwikPenINSULIN GLARGINE-AGLREli Lilly and Companyf6af8706-2058-4fe1-99c8-43684c20bfa22024-08-09Warnings, Adverse reactionsExact identifier
rxcui: 2589008
REZVOGLAR KWIKPENINSULIN GLARGINE-AGLRA-S Medication Solutions78888c87-7155-4e81-954d-cb40822ee27b2023-05-02Warnings, Adverse reactionsExact identifier
rxcui: 2589008

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
f6af8706-2058-4fe1-99c8-43684c20bfa2insulin glargine-aglr 300 UNT in 3 ML Pen Injector [PSN] · 3 ML insulin glargine-aglr 100 UNT/ML Pen Injector [SCD] · insulin glargine-aglr 300 UNT per 3 ML Pen Injector [SY]37These highlights do not include all the information needed to use REZVOGLAR safely and effectively. See full prescribing information for REZVOGLAR. REZVOGLAR (insulin glargine-aglr) injection, for subcutaneous use Initial U.S. Approval: 2021 REZVOGLAR (insulin glargine-aglr) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningfu20240809
78888c87-7155-4e81-954d-cb40822ee27binsulin glargine-aglr 300 UNT in 3 ML Pen Injector [PSN] · 3 ML insulin glargine-aglr 100 UNT/ML Pen Injector [SCD] · insulin glargine-aglr 300 UNT per 3 ML Pen Injector [SY]31These highlights do not include all the information needed to use REZVOGLAR safely and effectively. See full prescribing information for REZVOGLAR. REZVOGLAR (insulin glargine-aglr) injection, for subcutaneous use Initial U.S. Approval: 2021 REZVOGLAR (insulin glargine-aglr) is interchangeable An interchangeable product (IP) is a biological product that is approved based on data demonstrating that it is highly similar to an FDA-approved reference product (RP) and that there are no clinically meaningful diff20230502